Challenge Grant: Development of Nanoparticle-based Immunotherapy Against Refractory Cancer

Cancer immunotherapy is a potentially curative therapeutic for advanced cancer. In particular, chimeric antigen receptor (CAR) T-cell therapy showed marked efficacy against relapsed and refractory hematologic cancers and has already been in the clinic. However, the efficacy of CAR-T cell therapy for other cancers is still limited. T cells need to be optimally primed by antigen presenting cells to migrate to the solid tumor tissue through costimulation and cytokines, which are not necessarily proved for infused CAR-T cells. In this study, we will use a nanoparticle platform that induces complex immune cell activation signals to prime CAR-T cells in vivo. The developed particle will function as artificial antigen presenting system to allow CAR-T cells to infiltrate into tumor tissue.

About Project Members, Researchers.pdf

Note: ◎ indicates the project leader